MedPath

Prostaglandin E2

Generic Name
Prostaglandin E2
Brand Names
Cervidil, Prepidil, Prostin E2
Drug Type
Small Molecule
Chemical Formula
C20H32O5
CAS Number
363-24-6
Unique Ingredient Identifier
K7Q1JQR04M
Background

Dinoprostone is a naturally occurring prostaglandin E2 (PGE2). It has important effects in labour. It also stimulates osteoblasts to release factors which stimualtes bone resorption by osteoclasts. As a prescription drug it is used as a vaginal suppository, to prepare the cervix for labour and to induce labour.

Indication

For the termination of pregnancy during the second trimester (from the 12th through the 20th gestational week as calculated from the first day of the last normal menstrual period), as well as for evacuation of the uterine contents in the management of missed abortion or intrauterine fetal death up to 28 weeks of gestational age as calculated from the first day of the last normal menstrual period. Also used in the management of nonmetastatic gestational trophoblastic disease (benign hydatidiform mole). Other indications include improving the cervical inducibility (cervical "ripening") in pregnant women at or near term with a medical or obstetrical need for labor induction, and the management of postpartum hemorrhage.

Associated Conditions
Gestational Trophoblastic Neoplasia
Associated Therapies
Induction of cervix ripening therapy, Medically induced abortion, Uterus evacuation
Clinical Trials
Related News

FDA Clears Phase 2 Trial of TPST-1495 for Familial Adenomatous Polyposis Treatment

• Tempest Therapeutics received FDA clearance to proceed with a Phase 2 clinical trial of TPST-1495, a novel dual receptor inhibitor of prostaglandin signaling, for treating Familial Adenomatous Polyposis (FAP). • The study will evaluate TPST-1495's efficacy in reducing duodenal polyp burden in FAP patients who have undergone colectomy, with data expected in 2026. • The trial will be conducted by the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute's Division of Cancer Prevention, highlighting the need for innovative cancer prevention approaches.

Low-Level Laser Therapy Shows Promise in Accelerating Orthodontic Tooth Movement

• A recent umbrella review indicates that photobiomodulation with low-level lasers can effectively accelerate orthodontic tooth movement. • The review assessed multiple systematic reviews and meta-analyses, highlighting the potential of this therapy in orthodontic treatments. • Findings suggest low-level laser therapy could reduce the overall duration of orthodontic treatment with fixed appliances. • Further research is needed to standardize treatment protocols and optimize the application of photobiomodulation in orthodontics.

hUC-MSCs Show Promise in Treating Steroid-Refractory Acute Graft-versus-Host Disease

• A recent study investigates the efficacy of human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in treating steroid-refractory acute graft-versus-host disease (SR-aGVHD). • The trial, involving 7 Chinese centers, randomized patients to receive either hUC-MSCs or a placebo, alongside a second-line treatment for SR-aGVHD. • Results indicated a higher overall response rate at day 28 in the hUC-MSC group compared to the control, suggesting potential therapeutic benefits. • The study highlights hUC-MSCs as a promising option for patients with SR-aGVHD, warranting further investigation in larger clinical trials.

Anakinra Shows Promise in Reducing Endometriosis-Related Pain and Inflammation in Pilot Study

• A pilot study suggests that anakinra, an IL-1 antagonist, may reduce dysmenorrhea pain scores in women with endometriosis. • The study also found statistically significant improvements in quality of life, specifically in the domains of powerlessness and self-image. • Anakinra did not disrupt menstrual cycles, suggesting it may preserve fertility potential, a key advantage over current treatments. • Biomarker analysis revealed significantly lower levels of BDNF, an inflammatory marker, indicating a potential anti-inflammatory effect.

Efficacy and Safety of Piwei Peiyuan Prescription in Treating Chronic Atrophic Gastritis

A clinical trial demonstrates the effectiveness and safety of Piwei Peiyuan Prescription, a Traditional Chinese Medicine, in treating Chronic Atrophic Gastritis (CAG), a precancerous condition of the stomach. The study highlights the prescription's ability to improve symptoms, enhance gastrointestinal motility, and promote mucosal repair, with minimal adverse reactions.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy